Actively Recruiting
Phase 2 Study of Oral Olaparib Treatment in Adults With Homologous Recombination Deficient Malignant Mesothelioma
Led by University of Chicago · Updated on 2025-05-06
56
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of olaparib, a chemotherapy drug taken orally, in patients with malignant mesothelioma who have specific gene mutations related to homologous recombination deficiency HRD. This phase II trial aims to find out if olaparib can help shrink tumors or stop them from growing in these patients. The study focuses on patients with confirmed gene changes, including BAP1 loss or mutations disrupting protein function, who have previously been treated with platinum-based chemotherapy and have platinum-sensitive disease. Participants will receive olaparib pills twice daily in 28-day treatment cycles. They will visit the clinic on days 1 and 15 during the first cycle and then every 4 weeks on day 1 of each cycle until treatment ends. The study monitors treatment effects over time, including tumor response and patient survival, while tracking any side effects related to the drug. During the study, patients will undergo assessments such as tumor measurements using CT scans, genetic testing of tumor and normal cells, laboratory tests to check organ and bone marrow function, and evaluations of physical health status. Researchers will measure outcomes like how well the tumor responds to treatment, overall survival, progression-free survival, and the frequency of treatment side effects. The study lasts for up to two years for most outcomes, with some survival monitoring extending to three years.
CONDITIONS
Brief Title
Olaparib in Patients With HRD Malignant Mesothelioma
Research Team
H
Hedy L Kindler, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here